Panitumumab re-challenge strategy for liquid RAS mutation negative metastatic colorectal cancer

ABSTRACT: Interventions: Panitumumab 6 mg / kg and irinotecan 150 mg / m 2 are administered once every two weeks (14 days) until it meets protocol termination criteria. Primary outcome(s): Objective response rate:ORR (Investigator’s judgment based on RECIST guideline ver. 1.1) Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Ras/braf V600e Wild-type Unresectable Metastatic Colorectal Cancer

PROVIDER: 2614266 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR